6533b822fe1ef96bd127d699

RESEARCH PRODUCT

Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study

Camma'C. Di MarcoV. OrlandoA. SandonatoL. CasarilA. ParisiP. AlizziS. SciarrinoE. VirdoneR. PardoS. Di BonaD. LicataA. LatteriF. CabibboG. MontaltoG. Latteri MN. NicoliA. Craxi' Unita' Interdipartimentale Neoplasie Epatiche Uine Group

subject

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularCirrhosisGastroenterologyCohort StudiesInternal medicineHumansMedicineProspective StudiesProspective cohort studySurvival analysisAgedLaparotomyHepatologybusiness.industryProportional hazards modelLiver NeoplasmsMiddle AgedPrognosismedicine.diseaseSurvival AnalysisSurgeryHepatocellular carcinoma Radio frequency thermal ablation CirrhosisHepatocellular carcinomaCohortCatheter AblationFemaleNeoplasm Recurrence LocalbusinessLiver cancerFollow-Up StudiesCohort study

description

Abstract BACKGROUND/AIMS: To assess the effectiveness and the safety of radio-frequency thermal ablation (RFTA) in patients with hepatocellular carcinoma (HCC) or = 35 g/L, platelet count > or = 100.000/mmc, tumor size < or = 3 cm, complete response at 1 month and Barcelona Clinic Liver Cancer (BCLC) staging classification. Overall recurrence rates were 22, 38, and 44% at 12, 24, and 30 months, respectively. One procedure-related death occurred. The proportion of major complications after treatment was 3.9%. CONCLUSIONS: A complete response after RFTA significantly increases survival. The longest survival is obtained in the presence of HCC < or = 3 cm and of higher baseline albumin levels and platelet counts. BCLC staging classification is able to discriminate patients with good or poor prognosis.

yearjournalcountryeditionlanguage
2005-01-01
http://hdl.handle.net/10447/17879